Veracyte, Inc. (VCYT)

Market Cap	2.80B
Revenue (ttm)	479.13M
Net Income (ttm)	26.34M
Shares Out	78.67M
EPS (ttm)	0.34
PE Ratio	103.10
Forward PE	25.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	258,179
Open	34.89
Previous Close	34.61
Day's Range	34.67 - 35.50
52-Week Range	22.61 - 47.32
Beta	2.11
Analysts	Buy
Price Target	39.89 (+12.11%)
Earnings Date	Nov 5, 2025

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Analyst Summary

According to 9 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price target is $39.89, which is an increase of 12.11% from the latest price.

Price Target

$39.89

(12.11% upside)

Analyst Consensus: Buy